A5067096793- CAR-T cell therapy research
- Nanowire Synthesis and Applications
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Advancements in Semiconductor Devices and Circuit Design
- Advanced Biosensing Techniques and Applications
- Hippo pathway signaling and YAP/TAZ
- T-cell and B-cell Immunology
- Systemic Lupus Erythematosus Research
- Ubiquitin and proteasome pathways
- Advanced biosensing and bioanalysis techniques
- Extracellular vesicles in disease
- Molecular Biology Techniques and Applications
- Cancer Genomics and Diagnostics
- vaccines and immunoinformatics approaches
- Cancer Immunotherapy and Biomarkers
- Single-cell and spatial transcriptomics
Fred Hutch Cancer Center
2020-2025
University of Washington
2020-2024
North Seattle College
2022
National Cancer Institute
2020
Center for Cancer Research
2020
University of Connecticut
2017-2019
The interaction of the tumor necrosis factor receptor (TNFR) family member CD27 on naive CD8+ T (Tn) cells with homotrimeric CD70 antigen-presenting (APCs) is necessary for cell memory fate determination. Here, we examined signaling during Tn activation and differentiation. In conjunction (TCR) stimulation, ligation by a synthetic trimeric ligand triggered internalization degradation, suggesting active regulation this axis. Internalized recruited adaptor TRAF2 phosphatase SHP-1, thereby...
The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is effective in B cell malignancies. However, the persistence cancer with low levels or complete absence target antigen, thereby evading detection by CAR cells, leads to relapse. These evasion mechanisms highlight need for enhanced sensitivity and multispecificity. We introduce a synthetic receptor (ChTCR) that confers superior compared CARS previous hybrid TCR designs readily adapted bispecific targeting. ChTCRs...
By including oligonucleotide-labeled antibodies into high-throughput single-cell RNA-sequencing protocols, combined transcript and protein expression data can be acquired on the level. Here, we describe a protocol for analysis of over 40 proteins 400 genes 104 cells using nano-well based Rhapsody platform. We also include workflow sample multiplexing, which uniquely identifies initial source (such as tissue type or donor) in downstream after upstream pooling. For complete information use...
In order to gain mechanistic insights into multiple sclerosis (MS) pathogenesis, we utilized a multi-dimensional approach test the hypothesis that mutations in myelin proteins lead immune activation and central nervous system autoimmunity MS. Mass spectrometry-based proteomic analysis of human MS brain lesions revealed seven unique PLP1; key protein is known be destroyed Surprisingly, in-depth genomic two patients at DNA mRNA confirmed mutated PLP1 RNA, but not DNA. Quantification wild type...
The TMC genes encode a set of homologous transmembrane proteins whose functions are not well understood. Biallelic mutations in either TMC6 or TMC8 detected more than half cases the pre-malignant skin disease epidermodysplasia verruciformis (EV). It is controversial whether EV induced by originates from keratinocyte lymphocyte defects. Quantification and RNA levels various organs revealed that lymphoid tissues have highest expression both genes, custom antibodies confirmed protein mouse...
Recent advances in cancer immuno-therapeutics such as checkpoint inhibitors, chimeric antigen-receptor T cells, and tumor infiltrating cells (TIL) are now significantly impacting patients a positive manner. Although very promising, reports indicate no more than 25% of cases result complete remission. One the limitations these treatments is identity putative antigens each patient, it technically challenging to identify rapid fashion. Thus, identification followed by targeted treatment will...
Abstract The expression of a synthetic chimeric antigen receptor (CAR) to redirect specificity T cells is transforming the treatment hematological malignancies and autoimmune diseases [1-7]. In cancer, durable efficacy frequently limited by escape tumors that express low levels or lack target [8-12]. These clinical results emphasize need for immune receptors combine high sensitivity multispecificity improve outcomes. Current mono- bispecific CARs do not faithfully recapitulate cell (TCR)...